Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the release of five-year follow-up results for the Intismeran vaccine used ...

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

Moderna faces a $5b patent infringement lawsuit over its COVID-19 vaccine, now moving to trial after a key court ruling. The company is also appointing Dr. David Berman as Chief Development Officer, ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

Investing.com -- Moderna (NASDAQ:MRNA) stock rose 10% on Thursday, extending its winning streak to a fourth consecutive session and reaching its highest intraday level since November 2024.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for ...